CAMBRIDGE, Mass., March 16 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts have been accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL, April 14-18, 2010 in Vienna, Austria). Full abstracts can now be viewed at the EASL website at www.easl.eu.
The accepted abstracts are as follows:
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of chronic hepatitis C. For further information about Idenix, please refer to www.idenix.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements regarding the company's future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expects," "plans," "anticipates," "will," "estimates," "projects," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements, as are express or implied statements with respect to the company's clinical development programs or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates and expectations with respect to additional milestone payments, future royalty payments and cash balances at the end of 2009. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to: there can be no guarantees that historical sales of Tyzeka«/Sebivo« (telbivudine) will in any way suggest future royalty payments or royalty rates owed to the company, or that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaborations with Novartis Pharma AG and GlaxoSmithKline; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in the company's annual report on Form 10-K for the quarter ended December 31, 2009 as filed with the Securities and Exchange Commission (SEC), and in any subsequent periodic or current reports that the company files with the SEC.
All forward-looking statements reflect the company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the company's estimates change.
-- Lalezari, et al, "Antiviral Activity, Pharmacokinetics and Safety of IDX184 in Combination with Pegylated Interferon (PegIFN) and Ribavirin (RBV) in Treatment-Na´ve HCV Genotype 1-Infected Subjects", will be presented in a poster session beginning on Thursday, April 15.
SOURCE Idenix Pharmaceuticals, Inc.